Oncolytics Biotech (ONCY) Asset Utilization Ratio (2009 - 2025)

Oncolytics Biotech's (ONCY) quarterly Asset Utilization Ratio came in at 5.19 in Q3 2025, up 6.54% year-on-year from 4.87 in Q3 2024, and up 6.54% on a QoQ basis from 4.87 in Q3 2024.

Oncolytics Biotech (ONCY) Asset Utilization Ratio (2009 - 2025) Analysis & Trends

Oncolytics Biotech (ONCY) has 10 years of Asset Utilization Ratio data on file, last reported at 5.19 in Q3 2025.

  • On a quarterly basis, Asset Utilization Ratio rose 6.54% year-over-year to 5.19 in Q3 2025; TTM through Sep 2025 was 5.19, a 6.54% increase from a year earlier, with the FY2018 full-year figure at 1.08, changed N/A from the prior year.
  • Asset Utilization Ratio for Q3 2025 stood at 5.19, up from 4.87 in the prior quarter.
  • Over the last five years, Asset Utilization Ratio for ONCY reached as high as 5.19 in Q3 2025 and fell as low as 4.87 in Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Asset Util. (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 0.69
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 0.47
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 0.37
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Oncolytics Biotech 372.40 Mn 372.40 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 5.19
Sep 30, 2024 4.87
Sep 30, 2020 3.42
Jun 30, 2020 2.71
Mar 31, 2020 574,960.85
Sep 30, 2019 899,980.79
Jun 30, 2019 894,994.86
Mar 31, 2019 1.07 Mn
Dec 31, 2018 38,762.41
Sep 30, 2018 29,350.16
Jun 30, 2017 0.00
Jun 30, 2016 0.00
Jun 30, 2011 0.05
Sep 30, 2010 0.46
Jun 30, 2010 0.80
Sep 30, 2009 3.84
Jun 30, 2009 3.93
Mar 31, 2009 3.94